Today: 9 June 2026
Browse Category

BME:ITX 9 October 2025 - 8 February 2026

IBEX 35 Week Ahead: Spain’s Bolsa de Madrid Outlook After Inditex Record, Naturgy Shock and ECB Countdown (Updated Dec 14, 2025)

IBEX 35 Week Ahead: Spain’s Bolsa de Madrid Outlook After Inditex Record, Naturgy Shock and ECB Countdown (Updated Dec 14, 2025)

Spain’s IBEX 35 closed last week at 16,854.4, up 0.99%, after briefly touching 17,000 points for the first time. Banks led gains, with the IBEX 35 Banks index up 1.39% weekly and 103.39% year-to-date, while energy stocks lagged. Naturgy dropped 8.53% after BlackRock sold a 7.1% stake for €1.7 billion. Markets await ECB signals and year-end flows.
14 December 2025
···
Uzbekistan’s Big Bet: Import Fair 2025 Sparks a ‘Made in Uzbekistan’ Boom

Uzbekistan’s Big Bet: Import Fair 2025 Sparks a ‘Made in Uzbekistan’ Boom

Uzbekistan launched its first international Import Fair in Tashkent, unveiling $8.5 billion in new investment projects to boost local manufacturing and reduce imports. At the same time, 66 Uzbek firms promoted exports at MSV-2025 in Brno. GDP rose 7.2% year-on-year in early 2025, with FDI reaching $11.9 billion in 2024. Major foreign companies, including Inditex, praised recent trade reforms.
9 October 2025
·

Stock Market Today

  • SailPoint Q1 Earnings Beat Estimates Amid Revenue Growth
    June 9, 2026, 10:14 AM EDT. SailPoint, Inc. (SAIL) reported Q1 earnings of $0.05 per share, surpassing the Zacks Consensus Estimate of $0.04 by 17.65%. Revenue increased to $280.14 million, beating estimates by 1.41% and up from $230.47 million a year ago. Despite earnings surprises and revenue growth, SailPoint shares have declined 12.6% year-to-date against the S&P 500's 8.2% rise. The company holds a Zacks Rank #3 (Hold), indicating expected market-aligned performance. Consensus estimates forecast Q2 EPS of $0.08 on $310.79 million revenue and fiscal year EPS of $0.32 on $1.27 billion revenue. Industry trends in the Zacks Internet-Software sector will influence future stock performance. Investors await management's commentary for guidance on sustainability.

Latest articles

Regentis Biomaterials Stock: Tiny RGNT Is Back In Focus Before The Bell

Regentis Biomaterials Stock: Tiny RGNT Is Back In Focus Before The Bell

9 June 2026
Regentis Biomaterials shares dipped 2 cents to $1.28 premarket after the company announced European surgeon training for its GelrinC knee implant will begin in Q3, marking a key commercial step but leaving investors waiting for revenue proof as the stock trades far below its $8 IPO price.
IREN Stock Approaches $60 as AI Data-Center Bet Hits Key Point

IREN Stock Approaches $60 as AI Data-Center Bet Hits Key Point

9 June 2026
IREN surged 8.9% to $59.19 and was quoted higher premarket after a bitcoin rebound and renewed focus on its pivot to AI cloud infrastructure, but the stock remains exposed to bitcoin swings, heavy spending, and risks tied to its new 800MW South Australia data center project and major contracts with Nvidia and Microsoft.
AT&T Moves Higher Pre-Market on $45 Billion Payout Plan Still in Focus

AT&T Moves Higher Pre-Market on $45 Billion Payout Plan Still in Focus

9 June 2026
AT&T shares edged up to $22.58 pre-market after reaffirming 2026 guidance and a $45B+ shareholder return plan, providing a cash-flow marker as satellite broadband competition looms; the stock remains pressured by SpaceX risks flagged by Oppenheimer, with second-quarter free cash flow seen at $4.0–$4.5B.
GSK’s $10.6 Billion Oncology Leap Goes Deeper Than Headlines Show

GSK’s $10.6 Billion Oncology Leap Goes Deeper Than Headlines Show

9 June 2026
GSK will buy Nuvalent for $10.6 billion in cash, paying a 40% premium, to boost its oncology pipeline ahead of looming HIV drug patent expiries; Nuvalent shares jumped 38.9% premarket while GSK fell 1.4%, with the deal expected to add to GSK sales and profit from 2027 but dilute earnings per share 2026-2028 if it closes in Q3, and final outcome depends on FDA approvals and regulatory clearance.
Go toTop